TriangleElacestrant + T-DXd (NCT07198724)
Elacestrant + T-DXd trial for HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer (NCT07198724). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for adults with hormone receptor positive, HER2 low or HER2 ultralow metastatic breast cancer that has grown despite a CDK4/6 inhibitor and hormone therapy.
The idea: combine two drugs. Elacestrant is a pill that breaks down the estrogen receptor. Trastuzumab deruxtecan is an antibody drug conjugate that carries chemotherapy to cells with HER2 and is given by vein.
The study looks at safety and how well the combination works.
This phase 1 and 2 study plans 65 patients. At Dana-Farber Cancer Institute in Boston, Kristina Fanucci leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.